Tech Snapshot DCRecruiter 26 24915

Richard P. Feynman Center for Innovation

Technology Snapshot
Technology Licensing Opportunity

DC Recruiter

Learn more on SAM.gov
Explore additional LANL technologies:
m.lanl.gov/tech-search

Broad-Spectrum Immune Enhancer
Value Proposition
DC Recruiter: Broad-Spectrum Immune Enhancer
from scientists at Los Alamos National Laboratory
offers a differentiated approach to multi-pathogen
infection prevention by using a self-assembling
peptide nanofiber to recruit and activate dendritic
cells (DCs), the immune system’s natural sentinels.
Unlike pathogen-specific vaccines or therapeutics,
it is designed to help trigger an early immune
response regardless of the infecting agent.
Its needle-free, spray-friendly concept adds
practicality.

Technology Readiness Level 3
IP Information for S-195061

DC Recruiter solves this problem by using a specific
peptide selected to bind to dendritic cells. By leveraging a self-assembling peptide nanofiber platform, the technology is designed to help “wake up” immune surveillance early, before infection can progress unchecked. Rather than
relying on a treatment matched to one virus or bacterium, it creates the potential for broad-spectrum immune
support across many different infectious threats. Its ability to provide broad-spectrum immune support makes it
especially compelling for situations where time is critical and conventional options may be too specific, too slow
or too late to provide immediate protection. The needlefree, spray-friendly concept also adds practical value by supporting easier administration and broader accessibility, strengthening its fit for real-world use cases that demand rapid, flexible deployment.

Advantages
•

U.S. Patent pending

•

Contact Information

•

[email protected]

•

Technology Description

•

DC Recruiter addresses a persistent and highly
consequential gap in infection management: the need
for a rapid, broadly effective way to stimulate immune
defense before the specific pathogen is known. In many
exposure scenarios, the body encounters a threat before clinicians can identify the cause, and that delay can
reduce the effectiveness of conventional interventions. Current vaccines, antibiotics and antivirals are generally designed to act against a known target, which limits their usefulness when exposure is unexpected, diagnosis is
delayed or the pathogen is unfamiliar. That limitation
creates a clear unmet need for a fast-acting, broadspectrum approach that can be deployed early, with